TY - JOUR
T1 - Extracellular Vesicles
T2 - An Emerging Nanoplatform for Cancer Therapy
AU - Ma, Yifan
AU - Dong, Shiyan
AU - Li, Xuefeng
AU - Kim, Betty Y.S.
AU - Yang, Zhaogang
AU - Jiang, Wen
N1 - Publisher Copyright:
© Copyright © 2021 Ma, Dong, Li, Kim, Yang and Jiang.
PY - 2021/2/8
Y1 - 2021/2/8
N2 - Extracellular vesicles (EVs) are cell-derived membrane particles that represent an endogenous mechanism for cell-to-cell communication. Since discovering that EVs have multiple advantages over currently available delivery platforms, such as their ability to overcome natural barriers, intrinsic cell targeting properties, and circulation stability, the potential use of EVs as therapeutic nanoplatforms for cancer studies has attracted considerable interest. To fully elucidate EVs’ therapeutic function for treating cancer, all current knowledge about cellular uptake and trafficking of EVs will be initially reviewed. In order to further improve EVs as anticancer therapeutics, engineering strategies for cancer therapy have been widely explored in the last decade, along with other cancer therapies. However, therapeutic applications of EVs as drug delivery systems have been limited because of immunological concerns, lack of methods to scale EV production, and efficient drug loading. We will review and discuss recent progress and remaining challenges in developing EVs as a delivery nanoplatform for cancer therapy.
AB - Extracellular vesicles (EVs) are cell-derived membrane particles that represent an endogenous mechanism for cell-to-cell communication. Since discovering that EVs have multiple advantages over currently available delivery platforms, such as their ability to overcome natural barriers, intrinsic cell targeting properties, and circulation stability, the potential use of EVs as therapeutic nanoplatforms for cancer studies has attracted considerable interest. To fully elucidate EVs’ therapeutic function for treating cancer, all current knowledge about cellular uptake and trafficking of EVs will be initially reviewed. In order to further improve EVs as anticancer therapeutics, engineering strategies for cancer therapy have been widely explored in the last decade, along with other cancer therapies. However, therapeutic applications of EVs as drug delivery systems have been limited because of immunological concerns, lack of methods to scale EV production, and efficient drug loading. We will review and discuss recent progress and remaining challenges in developing EVs as a delivery nanoplatform for cancer therapy.
KW - cancer therapy
KW - drug delivery
KW - exosome
KW - extracellular vesicle
KW - therapeutic nanoplatform
UR - http://www.scopus.com/inward/record.url?scp=85101394480&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101394480&partnerID=8YFLogxK
U2 - 10.3389/fonc.2020.606906
DO - 10.3389/fonc.2020.606906
M3 - Review article
C2 - 33628730
AN - SCOPUS:85101394480
SN - 2234-943X
VL - 10
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 606906
ER -